Towards hepatitis C virus elimination:Egyptian experience,achievements and limitations

作     者：Dalia Omran Mohamed Alboraie Rania A Zayed Mohamed-Naguib Wifi Mervat Naguib Mohamed Eltabbakh Mohamed Abdellah Ahmed Fouad Sherief Sahar Maklad Heba Hamdy Eldemellawy Omar Khalid Saad Doaa Mohamed Khamiss Mohamed El Kassas 

作者机构：Department of Endemic Medicine and HepatologyFaculty of MedicineCairo UniversityCairo 11651Egypt Department of Endemic MedicineFaculty of MedicineHelwan UniversityCairo 11599Egypt Department of Internal MedicineAl-Azhar UniversityCairo 11651Egypt Department of Clinical and Chemical PathologyFaculty of MedicineCairo UniversityCairo 11651Egypt Department of Internal MedicineFaculty of MedicineCairo UniversityCairo 11599Egypt Department of Tropical MedicineFaculty of MedicineAin Shams UniversityCairo 11566Egypt National Hepatology and Tropical Medicine Research InstituteCairo 11599Egypt Department of Internal MedicineFaculty of MedicineBeni-Suef UniversityBeni-Suef 62511Egypt Faculty of MedicineAin Shams UniversityCairo 11566Egypt Department of Clinical and Chemical PathologyEl-monera hospitalMinistry of HealthCairo 11562Egypt 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2018年第24卷第38期

页      面：4330-4340页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Hepatitis C virus Egypt Direct acting antivirals screening elimination Limitations 

摘      要：Worldwide, more than one million people die each year from hepatitis C virus(HCV) related diseases, and over 300 million people are chronically infected with hepatitis B or C. Egypt used to be on the top of the countries with heavy HCV burden. Some countries are making advances in elimination of HCV, yet multiple factors preventing progress; remain for the majority. These factors include lack of global funding sources for treatment, late diagnosis, poor data, and inadequate screening. Treatment of HCV in Egypt has become one of the top national priorities since 2007. Egypt started a national treatment program intending to provide cure for Egyptian HCV-infected patients. Mass HCV treatment program had started using Pegylated interferon and ribavirin between 2007 and 2014. Yet, with the development of highly-effective direct acting antivirals(DAAs) for HCV, elimination of viral hepatitis has become a real possibility. The Egyptian National Committee for the Control of Viral Hepatitis did its best to provide Egyptian HCV patients with DAAs. Egypt adopted a strategy that represents a model of care that could help other countries with high HCV prevalence rate in their battle against HCV. This review covers the effects of HCV management in Egyptian real life settings and the outcome of different treatment protocols. Also, it deals with the current and future strategies for HCV prevention and screening as well as the challenges facing HCV elimination and the prospect of future eradication of HCV.